The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
Key result
SwedeHF enrollment linked to ~20% lower mortality versus the National Patient Registry alone.
- RR 0.8
- 95% CI 0.78-0.82
- P<0.001
- n=101,303
Population
63,519 unique patients with heart failure registered in the Swedish Heart Failure Registry up to December…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May indicate selection or care differences; leaves open whether SwedeHF enrollment causally improves HF survival.
Key Points
- To explore how the Swedish Heart Failure Registry can enhance understanding and management of heart failure, focusing on treatment gaps and ongoing characterization of HF types.
- Descriptive analysis of registry data
- Identification of treatment patterns
- Assessment of treatment efficacy in heart failure types
- Current treatments for HFrEF are often underutilized
- No evidence-based treatments exist for HFmrEF
- Previous trials in HFpEF have not yielded effective therapies
Study Design
Type
Observational (n=101,303)
Multicenter
Yes
Structured PICO
P
Population
63,519 unique patients with heart failure registered in the Swedish Heart Failure Registry (SwedeHF) up to December 31, 2014.
Main Result
Effect estimate: RR 0.8 (95% CI 0.78-0.82)
p-value: p=<0.001
SwedeHF serves as a powerful nationwide platform for quality assurance, real-world observational research, and registry-based randomized controlled trials in heart failure.
Limitations
- Use of observational data limits causal inference about treatment efficacy.
Cite This Study
Savarese et al. (2018) conducted an observational in Heart Failure (n=101,303). SwedeHF vs. National Patient Registry was evaluated on Mortality reduction in registered patients versus those not registered (RR 0.8, 95% CI 0.78-0.82, p=<0.001). Enrollment in SwedeHF was associated with a 20% reduction in mortality compared to those registered only in the National Patient Registry.